Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich

Research output: Contribution to journalArticle

369 Citations (Scopus)

Abstract

This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases inBCR-ABL transcripts over time. Analyses of event-free survival (EFS) and time to progression to accelerated phase/blast crisis (AP/BC) at 7 years were based on molecular responses using the international scale (IS) at 6-, 12-, and 18-month landmarks. Patients with BCR-ABL transcripts > 10% at 6 months and > 1% at 12 months had inferior EFS and higher rate of progression to AP/BC compared with all other molecular response groups. Conversely, patients who achieved major molecular response [MMR: BCR-ABL (IS) ≤ 0.1%] by 18 months enjoyed remarkably durable responses, with no progression to AP/BC and 95% EFS at 7 years. The probability of loss of complete cytogenetic response by 7 years was only 3% for patients in MMR at 18 months versus 26% for patients with complete cytogenetic response but not MMR (P < .001). This study shows a strong association between the degree to which BCR-ABL transcript numbers are reduced by therapy and long-term clinical outcome, supporting the use of time-dependent molecular measures to determine optimal response to therapy. This study is registered at www.clinicaltrials.gov as NCT00006343.

LanguageEnglish
Pages3758-3765
Number of pages8
JournalBlood
Volume116
Issue number19
DOIs
Publication statusPublished - 11 Nov 2010

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Hughes, Timothy P. ; Hochhaus, Andreas ; Branford, Susan ; Müller, Martin C. ; Kaeda, Jaspal S. ; Foroni, Letizia ; Druker, Brian J. ; Guilhot, François ; Larson, Richard A. ; O'Brien, Stephen G. ; Rudoltz, Marc S. ; Mone, Manisha ; Wehrle, Elisabeth ; Modur, Vijay ; Goldman, John M. ; Radich, Jerald P. / Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : An analysis from the International Randomized Study of Interferon and STI571 (IRIS). In: Blood. 2010 ; Vol. 116, No. 19. pp. 3758-3765.
@article{557ffcaffe084f17b9559d9999475707,
title = "Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS)",
abstract = "This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases inBCR-ABL transcripts over time. Analyses of event-free survival (EFS) and time to progression to accelerated phase/blast crisis (AP/BC) at 7 years were based on molecular responses using the international scale (IS) at 6-, 12-, and 18-month landmarks. Patients with BCR-ABL transcripts > 10{\%} at 6 months and > 1{\%} at 12 months had inferior EFS and higher rate of progression to AP/BC compared with all other molecular response groups. Conversely, patients who achieved major molecular response [MMR: BCR-ABL (IS) ≤ 0.1{\%}] by 18 months enjoyed remarkably durable responses, with no progression to AP/BC and 95{\%} EFS at 7 years. The probability of loss of complete cytogenetic response by 7 years was only 3{\%} for patients in MMR at 18 months versus 26{\%} for patients with complete cytogenetic response but not MMR (P < .001). This study shows a strong association between the degree to which BCR-ABL transcript numbers are reduced by therapy and long-term clinical outcome, supporting the use of time-dependent molecular measures to determine optimal response to therapy. This study is registered at www.clinicaltrials.gov as NCT00006343.",
author = "Hughes, {Timothy P.} and Andreas Hochhaus and Susan Branford and M{\"u}ller, {Martin C.} and Kaeda, {Jaspal S.} and Letizia Foroni and Druker, {Brian J.} and Fran{\cc}ois Guilhot and Larson, {Richard A.} and O'Brien, {Stephen G.} and Rudoltz, {Marc S.} and Manisha Mone and Elisabeth Wehrle and Vijay Modur and Goldman, {John M.} and Radich, {Jerald P.}",
year = "2010",
month = "11",
day = "11",
doi = "10.1182/blood-2010-03-273979",
language = "English",
volume = "116",
pages = "3758--3765",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

Hughes, TP, Hochhaus, A, Branford, S, Müller, MC, Kaeda, JS, Foroni, L, Druker, BJ, Guilhot, F, Larson, RA, O'Brien, SG, Rudoltz, MS, Mone, M, Wehrle, E, Modur, V, Goldman, JM & Radich, JP 2010, 'Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS)', Blood, vol. 116, no. 19, pp. 3758-3765. https://doi.org/10.1182/blood-2010-03-273979

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : An analysis from the International Randomized Study of Interferon and STI571 (IRIS). / Hughes, Timothy P.; Hochhaus, Andreas; Branford, Susan; Müller, Martin C.; Kaeda, Jaspal S.; Foroni, Letizia; Druker, Brian J.; Guilhot, François; Larson, Richard A.; O'Brien, Stephen G.; Rudoltz, Marc S.; Mone, Manisha; Wehrle, Elisabeth; Modur, Vijay; Goldman, John M.; Radich, Jerald P.

In: Blood, Vol. 116, No. 19, 11.11.2010, p. 3758-3765.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia

T2 - Blood

AU - Hughes, Timothy P.

AU - Hochhaus, Andreas

AU - Branford, Susan

AU - Müller, Martin C.

AU - Kaeda, Jaspal S.

AU - Foroni, Letizia

AU - Druker, Brian J.

AU - Guilhot, François

AU - Larson, Richard A.

AU - O'Brien, Stephen G.

AU - Rudoltz, Marc S.

AU - Mone, Manisha

AU - Wehrle, Elisabeth

AU - Modur, Vijay

AU - Goldman, John M.

AU - Radich, Jerald P.

PY - 2010/11/11

Y1 - 2010/11/11

N2 - This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases inBCR-ABL transcripts over time. Analyses of event-free survival (EFS) and time to progression to accelerated phase/blast crisis (AP/BC) at 7 years were based on molecular responses using the international scale (IS) at 6-, 12-, and 18-month landmarks. Patients with BCR-ABL transcripts > 10% at 6 months and > 1% at 12 months had inferior EFS and higher rate of progression to AP/BC compared with all other molecular response groups. Conversely, patients who achieved major molecular response [MMR: BCR-ABL (IS) ≤ 0.1%] by 18 months enjoyed remarkably durable responses, with no progression to AP/BC and 95% EFS at 7 years. The probability of loss of complete cytogenetic response by 7 years was only 3% for patients in MMR at 18 months versus 26% for patients with complete cytogenetic response but not MMR (P < .001). This study shows a strong association between the degree to which BCR-ABL transcript numbers are reduced by therapy and long-term clinical outcome, supporting the use of time-dependent molecular measures to determine optimal response to therapy. This study is registered at www.clinicaltrials.gov as NCT00006343.

AB - This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases inBCR-ABL transcripts over time. Analyses of event-free survival (EFS) and time to progression to accelerated phase/blast crisis (AP/BC) at 7 years were based on molecular responses using the international scale (IS) at 6-, 12-, and 18-month landmarks. Patients with BCR-ABL transcripts > 10% at 6 months and > 1% at 12 months had inferior EFS and higher rate of progression to AP/BC compared with all other molecular response groups. Conversely, patients who achieved major molecular response [MMR: BCR-ABL (IS) ≤ 0.1%] by 18 months enjoyed remarkably durable responses, with no progression to AP/BC and 95% EFS at 7 years. The probability of loss of complete cytogenetic response by 7 years was only 3% for patients in MMR at 18 months versus 26% for patients with complete cytogenetic response but not MMR (P < .001). This study shows a strong association between the degree to which BCR-ABL transcript numbers are reduced by therapy and long-term clinical outcome, supporting the use of time-dependent molecular measures to determine optimal response to therapy. This study is registered at www.clinicaltrials.gov as NCT00006343.

UR - http://www.scopus.com/inward/record.url?scp=77958595179&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-03-273979

DO - 10.1182/blood-2010-03-273979

M3 - Article

VL - 116

SP - 3758

EP - 3765

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -